Understanding the fibromyalgia syndrome
Srinivas G Rao1, Judith F Gendreau, Jay D Kranzler
1Cypress Bioscience, Inc., San Diego, CA, USA.
Psychopharmacology Bulletin
|January 30, 2008
Summary
Fibromyalgia syndrome (FMS) causes widespread chronic pain. This review covers FMS pathophysiology and treatments, focusing on pain processing, neurotransmitters, and current drug therapies for psychiatrists.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Fibromyalgia syndrome (FMS) is a leading cause of chronic, widespread pain.
- Understanding FMS pathophysiology is crucial for effective treatment strategies.
Purpose of the Study:
- To provide a comprehensive review of FMS pathophysiology and treatment.
- To summarize the current state of knowledge for psychiatry and psychopharmacology professionals.
Main Methods:
- Review of pain pathway anatomy and physiology.
- Analysis of altered biological mechanisms in FMS, including neurotransmitter function and neuroendocrine systems.
- Critical evaluation of existing pharmacological treatments for FMS.
Main Results:
- Detailed summary of FMS-related pain processing alterations.
- Overview of neurotransmitter and neuroendocrine system dysfunctions in FMS.
- Categorization and critical review of current FMS drug therapies.
Conclusions:
- FMS involves complex alterations in pain processing and neurobiology.
- Current pharmacological treatments offer various approaches to managing FMS symptoms.
- Further research is needed to refine FMS treatment strategies.
Related Concept Videos
01:21Layers of Connective Tissue Proper
Fascia, a thin layer of fibrous connective tissue, is distributed throughout the body. It demarcates and forms a supportive covering over skeletal muscles, bones, blood vessels, and organs. There are three main types of facia— superficial fascia, deep fascia, and subserous fascia. These are all present at different depths in the body. Fascia reduces the friction and permits muscles, joints, and organs to easily slide against each other, facilitating movement of the body and preventing tearing...
01:23Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...